Edesa Biotech, Inc. (EDSA): CEO Dr. Pardeep Nijhawan compensation terms

Events in this filing

Item 5.02 as filed

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 23, 2026, the Board of Directors (the
“Board”) of Edesa Biotech, Inc. (the “Company”), upon the recommendation of the Compensation Committee of
the Board, approved increases in the annual base salaries of Dr. Pardeep Nijhawan, the Company’s Chief Executive Officer, from
$357,696 to $657,423, Dr. Michael Brooks, the Company’s President, from $335,340 to $591,681, and Peter Weiler, the
Company’s Chief Financial Officer, from $300,000 to $525,938, in each case pursuant to their respective employment agreements
with the Company and retroactive to July 1, 2026. Prior to the foregoing increases, the base salaries of the Company’s executive officers had last been adjusted
in 2023.
As previously disclosed, 90% of Dr. Nijhawan’s monthly
base salary otherwise payable in cash will continue to be issued in the form of fully vested restricted share units under the Company’s
2019 Equity Incentive Compensation Plan.
The foregoing descriptions of the compensatory arrangements of
Dr. Nijhawan, Dr. Brooks and Mr. Weiler do not purport to be complete and are qualified in their entirety by reference to their respective
employment agreements, which are filed as exhibits to the Company’s Annual Report on Form 10-K for the year ended September 30,
2025, filed on December 12, 2025, and incorporated herein by reference.